GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » EPS without NRI

Telomir Pharmaceuticals (Telomir Pharmaceuticals) EPS without NRI : $-0.66 (TTM As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals EPS without NRI?

Telomir Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Mar. 2024 was $-0.23. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.66.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Telomir Pharmaceuticals's EPS without NRI or its related term are showing as below:

TELO's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 5.45
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Telomir Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.23. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.66.

Telomir Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2024 was $-0.23. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.66.


Telomir Pharmaceuticals EPS without NRI Historical Data

The historical data trend for Telomir Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals EPS without NRI Chart

Telomir Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23
EPS without NRI
-0.01 -0.03 -0.19

Telomir Pharmaceuticals Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS without NRI Get a 7-Day Free Trial Premium Member Only -0.02 -0.05 -0.06 -0.32 -0.23

Competitive Comparison of Telomir Pharmaceuticals's EPS without NRI

For the Biotechnology subindustry, Telomir Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telomir Pharmaceuticals's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telomir Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Telomir Pharmaceuticals's PE Ratio without NRI falls into.



Telomir Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telomir Pharmaceuticals  (NAS:TELO) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Telomir Pharmaceuticals EPS without NRI Related Terms

Thank you for viewing the detailed overview of Telomir Pharmaceuticals's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Telomir Pharmaceuticals (Telomir Pharmaceuticals) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Headlines